We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Bitter pill

6 October 2021 By Jonathan Guilford

Firms navigating a merger crackdown by the FTC are facing uncertainty. That should in theory be good for arb investors. The trouble is some, like Kadmon and Sanofi in their $1.9 bln deal, are cautiously planning for the worst, making it nearly impossible for arbs to cash in.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)